Actively Recruiting
Randomized, Double-blind, Placebo-controlled Study Evaluating Safety and Food Effect of ACCG-2671 in Adults With and Without Obesity
Led by Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics · Updated on 2026-09-14
164
Participants Needed
6
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ACCG-2671, a nonpeptide dual amylin and calcitonin receptor agonist, in a first-in-human study to assess its safety, tolerability, and how the body processes the drug. The study includes healthy adults and adults with obesity and investigates the impact of food on the drugs effects. This randomized, double-blind trial is sponsored by Aconcagua Bio, Inc. The study has three parts Part 1 tests single ascending oral doses of ACCG-2671 or placebo in healthy participants Part 2 assesses the effect of food on a single dose in healthy participants under fasted and fed states and Part 3 evaluates multiple ascending daily doses over 84 days in adults with obesity, including those on stable injectable GLP-1RA treatment. Safety committees review data before increasing doses. Participants will undergo screening and then receive assigned doses or placebo, with monitoring including clinical evaluations, laboratory tests, vital signs, and ECGs over specified periods ranging from 17 to 112 days depending on the study part. Researchers track adverse events and changes in various blood and heart function measures. The study runs from December 2025 to April 2027, with detailed follow-up during and after dosing periods.
CONDITIONS
Brief Title
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Research Team
S
Sara Ahmed MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here